Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

838 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM; ATLAS ACS-TIMI 46 study group. Mega JL, et al. Among authors: burton p. Lancet. 2009 Jul 4;374(9683):29-38. doi: 10.1016/S0140-6736(09)60738-8. Epub 2009 Jun 17. Lancet. 2009. PMID: 19539361 Clinical Trial.
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, Plotnikov A, Sun X, Cook-Bruns N, Braunwald E. Gibson CM, et al. Among authors: burton p. Am Heart J. 2011 May;161(5):815-821.e6. doi: 10.1016/j.ahj.2011.01.026. Am Heart J. 2011. PMID: 21570509 Clinical Trial.
Rivaroxaban in patients with a recent acute coronary syndrome.
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators. Mega JL, et al. Among authors: burton p. N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13. N Engl J Med. 2012. PMID: 22077192 Free article. Clinical Trial.
Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG, Parkhomenko A, Tendera M, Widimsky P, Gibson CM. Mega JL, et al. Among authors: burton p. J Am Coll Cardiol. 2013 May 7;61(18):1853-9. doi: 10.1016/j.jacc.2013.01.066. Epub 2013 Mar 7. J Am Coll Cardiol. 2013. PMID: 23500262 Free article. Clinical Trial.
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW, Bhatt DL, Goto S, Cohen M, Mohanavelu S, Burton P, Stone G, Braunwald E; ATLAS-ACS 2 TIMI 51 Investigators. Gibson CM, et al. Among authors: burton p. J Am Coll Cardiol. 2013 Jul 23;62(4):286-90. doi: 10.1016/j.jacc.2013.03.041. Epub 2013 Apr 16. J Am Coll Cardiol. 2013. PMID: 23602776 Free article. Clinical Trial.
Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Korjian S, Braunwald E, Daaboul Y, Verheugt F, Bode C, Tendera M, Jain P, Plotnikov A, Burton P, Gibson CM. Korjian S, et al. Among authors: burton p. Eur Heart J Acute Cardiovasc Care. 2019 Mar;8(2):186-193. doi: 10.1177/2048872617745003. Epub 2017 Dec 18. Eur Heart J Acute Cardiovasc Care. 2019. PMID: 29249166 Clinical Trial.
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
Korjian S, Braunwald E, Daaboul Y, Mi M, Bhatt DL, Verheugt FWA, Cohen M, Bode C, Burton P, Plotnikov AN, Gibson CM. Korjian S, et al. Among authors: burton p. Am J Cardiol. 2018 Dec 1;122(11):1896-1901. doi: 10.1016/j.amjcard.2018.08.034. Epub 2018 Sep 7. Am J Cardiol. 2018. PMID: 30340765 Free article. Clinical Trial.
The treatment of missing data in a large cardiovascular clinical outcomes study.
Little RJ, Wang J, Sun X, Tian H, Suh EY, Lee M, Sarich T, Oppenheimer L, Plotnikov A, Wittes J, Cook-Bruns N, Burton P, Gibson CM, Mohanty S. Little RJ, et al. Among authors: burton p. Clin Trials. 2016 Jun;13(3):344-51. doi: 10.1177/1740774515626411. Epub 2016 Feb 17. Clin Trials. 2016. PMID: 26908543
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.
Sarich TC, Peters G, Berkowitz SD, Misselwitz F, Nessel CC, Burton P, Cook-Bruns N, Lensing AW, Haskell L, Perzborn E, Kubitza D, Moore KT, Jalota S, Weber J, Pan G, Sun X, Westermeier T, Nadel A, Oppenheimer L, DiBattiste PM. Sarich TC, et al. Among authors: burton p. Ann N Y Acad Sci. 2013 Jul;1291:42-55. doi: 10.1111/nyas.12136. Epub 2013 May 23. Ann N Y Acad Sci. 2013. PMID: 23701516 Review.
838 results